Search
Omni Bridgeway chief executive Andrew Saker.

Omni Bridgeway on front foot

The biggest player in Australia’s litigation funding market has supported new licensing rules proposed by the federal government while also pushing for the new requirements to be extended to law firms.

Login

(existing subscribers)

The password field is case sensitive.
Request new password

Share Price

Closing price for the last 90 trading days
Powered by Morningstar ®

Total Shareholder Return as at 30/04/20

1 year TSR5 year TSR
thOpenDNA
142ndOmni Bridgeway47%20%
253rdZelira Therapeutics10%12%
647thAusCann Group Holdings-49%27%
674 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®

Share Transactions

20/03/20
$748 Issued
20/03/20
$5k Issued
20/03/20
$33k Issued
Total value as at the date of the transaction
Powered by Morningstar ®

Revenue

127th↓Omni Bridgeway$1.6m
145th-Ocean Grown Abalone$844k
146th↑Zelira Therapeutics$769k
149th↑OpenDNA$706k
151st↑AusCann Group Holdings$671k
197 listed industrial companies ranked by revenue.
Powered by Morningstar ®